Stock Option Programs, Proposed Refinancing, FDA Approvals, and Conference Presentations - Analyst Notes on Aegerion, DaVita, DexCom, Impax and Sanofi

NEW YORK, June 11, 2014 /PRNewswire/ --

Today, Analysts Review released its analysts' notes regarding Aegerion Pharmaceuticals, Inc. (NASDAQ: AEGR), DaVita HealthCare Partners Inc (NYSE: DVA), DexCom, Inc. (NASDAQ: DXCM), Impax Laboratories Inc (NASDAQ: IPXL) and Sanofi SA (ADR) (NYSE: SNY). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/3596-100free.

--
Aegerion Pharmaceuticals, Inc. Analyst Notes
On June 6, 2014, Aegerion Pharmaceuticals, Inc. (Aegerion) announced that on June 2, 2014, it granted stock options to purchase an aggregate of 18,300 shares of common stock to four new employees under an inducement stock option program. According to the Company, under the inducement stock option program, each stock option has an exercise price per share of $30.40 (the closing price of Aegerion's common stock on the grant date), vests 25% after a year of the date of grant with the remaining 75% to vest in monthly installments over the three following years, has a ten year term, and is subject to terms and conditions of Aegerion's Inducement Award Stock Option Plan, and the terms and conditions of a stock option agreement that covers the grant. The full analyst notes on Aegerion are available to download free of charge at:

http://www.analystsreview.com/Jun-11-2014/AEGR/report.pdf

--
DaVita HealthCare Partners Inc Analyst Notes
On June 2, 2014, DaVita HealthCare Partners Inc (DaVita) announced that it is proposing to enter into $5.5 billion of new senior secured credit facilities which consists of a $1.0 billion revolving credit facility, a $1.0 billion term loan A and a $3.5 billion term loan B, and to issue an aggregate principal amount of up to $1.75 billion of unsecured debt, subject to market and other conditions. According to the Company, it intends to use the net proceeds of the unsecured debt offering, together with the new term loans, to refinance the Company's existing credit facilities as well as the existing $775 million 6.375% senior notes due 2018, and also for general corporate purposes. The full analyst notes on DaVita are available to download free of charge at:

http://www.analystsreview.com/Jun-11-2014/DVA/report.pdf

--
DexCom, Inc. Analyst Notes
On June 3, 2014, DexCom, Inc. (DexCom) announced that it has received approval from the U.S. Food and Drug Administration (FDA) for its Dexcom G4® PLATINUM Professional continuous glucose monitoring (CGM), the only professional-version CGM that offers real-time and unblinded feedback that allows patients to experience the full benefits of real-time CGM and provides doctors with an opportunity to review glucose data retrospectively with the patient to make therapeutic treatment recommendations. Dexcom stated that clinicians can use the insights gained from a professional CGM session to adjust therapy and to educate and encourage patients to modify their behavior after seeing the effects of specific food, exercise, stress, and medications on their glucose levels. According to the Company, professional CGMs are perfect for patients who struggle to meet glycemic goals, suffer from frequent hypoglycemia, or have wide fluctuations in glycemic variability. The full analyst notes on DexCom are available to download free of charge at:

http://www.analystsreview.com/Jun-11-2014/DXCM/report.pdf

--
Impax Laboratories Inc Analyst Notes
On June 6, 2014, Impax Laboratories Inc (Impax) announced the participation of its President and CEO Fred Wilkinson, and CFO Bryan M. Reasons, at the Goldman Sachs 35th Annual Global Healthcare Conference on Thursday, June 12, 2014, at 8:40 a.m. PT. Impax stated that the event will be webcast live and can be accessed under the Investor Relations section of the Company's website. The full analyst notes on Impax are available to download free of charge at:

http://www.analystsreview.com/Jun-11-2014/IPXL/report.pdf

--
Sanofi SA (ADR) Analyst Notes
On May 30, 2014, Sanofi SA (ADR) (Sanofi) and Genzyme, its subsidiary, announced that the U.S. Food and Drug Administration (FDA) has accepted for review the Company's resubmission of its supplemental Biologics License Application (sBLA) for approval of Lemtrada™ (alemtuzumab) used for the treatment of relapsing forms of multiple sclerosis. According to the Company, a six-month period has been granted for the Lemtrada sBLA, and Genzyme expects FDA action on the sBLA in Q4 2014. The full analyst notes on Sanofi are available to download free of charge at:

http://www.analystsreview.com/Jun-11-2014/SNY/report.pdf

--
About Analysts Review
We do things differently. Our goal is to provide the best content to our exclusive membership. We are constantly hiring researchers, writers, editors and analysts to add to our team and become better than yesterday. If being a part of a fast growing community with an edge in today's market sounds interesting to you, then sign-up today and experience the full benefits of membership.


===============
EDITOR'S NOTES:
===============

1. This is not company news. We are an independent source and our views do not reflect the companies mentioned.

2. Information in this release is produced on a best efforts basis by Rohit Tuli, a CFA charterholder. The content is then further fact checked and reviewed by an outsourced research provider. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.

3. This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.

4. If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco [at] http://www.analystsreview.com.

5. For any urgent concerns or inquiries, please contact us at compliance [at] http://www.analystsreview.com.

6. Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research [at] http://www.analystsreview.com for consideration.

COMPLIANCE PROCEDURE
Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Analysts Review, represented by Rohit Tuli, CFA. An outsourced research services provider has only reviewed the information provided by Analysts Review in this article or report according to the procedures outlined by Analysts Review. Analysts Review is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.

NOT FINANCIAL ADVICE
Analysts Review makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED
Analysts Review is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Analysts Review whatsoever for any direct, indirect or consequential loss arising from the use of this document. Analysts Review expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Analysts Review does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE Analysts Review

WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?

440k+
Newsrooms &
Influencers

9k+
Digital Media
Outlets

270k+
Journalists
Opted In

GET STARTED